EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Clinical heterogeneity and therapeutic options for idiopathic infantile hypercalcemia caused by CYP24A1 pathogenic variant

Zhichao Zheng iD, Yujie Wu, Huiping Wu, Jiahui Jin, Yue Luo, Shunshun Cao, Xiaoou Shan

Journal of Pediatric Endocrinology and Metabolism · 2023

DOI: 10.1515/jpem-2023-0147 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Pediatric Endocrinology and Metabolism, 2023. Verfasst von Zhichao Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Endocrinology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang…. Hauptthemen laut MEDLINE: Hypercalcemia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 83 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives Infantile hypercalcemia-1 (HCINF1) is a rare disease caused by pathogenic variants in the CYP24A1 gene, resulting in the inability to metabolize active vitamin D. This leads to hypercalcemia and severe complications. Content On December 8th, 2022, a systematic literature search was conducted in PubMed, Wanfang, and CNKI using the keywords “hypercalcemia” and “ CYP24A1 ”. Data extraction included patient demographics, clinical presentation, treatment medications, and outcomes. The findings were synthesized to identify common patterns and variations among cases and to assess the efficacy of different therapies in reducing serum calcium. Our findings revealed two distinct peaks in the incidence of HCINF1 caused by CYP24A1 pathogenic variant. Kidney stones or renal calcifications were the most common clinical manifestations of the disease, followed by polyuria and developmental delay. Laboratory investigations showed hypercalcemia, elevated vitamin D levels, hypercalciuria, and low parathyroid hormone. Genetic analysis remains the only reliable diagnostic tool. Although there is no definitive cure for HCINF1, multiple drugs, including bisphosphonates, calcitonin, and rifampicin, have been used to control its symptoms. Blocking the production and intake of vitamin D is the preferred treatment option. Summary and outlook Our review highlights the basic clinical and biochemical features of HCINF1 and suggests that targeted diagnostic and therapeutic strategies are needed to address the clinical heterogeneity of the disease. The insights gained from this study may facilitate the development of innovative treatments for HCINF1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypercalcemiaMutationInfant, Newborn, DiseasesVitamin DMetabolism, Inborn ErrorsVitaminsHumansVitamin D3 24-Hydroxylase

Stichwörter der Autor:innen

CYP24A1bisphosphonateshypercalcemiainfantvitamin D

Substanzen

Vitamin D3 24-HydroxylaseVitamin DVitaminsCYP24A1 protein, human

Autor:innen und Institutionen

  • Department of Pediatric Endocrinology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, P.R. China.
  • The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, P.R. China.

ORCID-Profile: Zhichao Zheng

Zitieren

APA

Zheng, Z., Wu, Y., Wu, H., Jin, J., Luo, Y., Cao, S., & Shan, X. (2023). Clinical heterogeneity and therapeutic options for idiopathic infantile hypercalcemia caused by CYP24A1 pathogenic variant. Journal of Pediatric Endocrinology and Metabolism. https://doi.org/10.1515/jpem-2023-0147

Vancouver

Zheng Z, Wu Y, Wu H, Jin J, Luo Y, Cao S, et al. Clinical heterogeneity and therapeutic options for idiopathic infantile hypercalcemia caused by CYP24A1 pathogenic variant. Journal of Pediatric Endocrinology and Metabolism. 2023. doi:10.1515/jpem-2023-0147

BibTeX
@article{Zheng2023,
  author = {Zheng, Zhichao and Wu, Yujie and Wu, Huiping and Jin, Jiahui and Luo, Yue and Cao, Shunshun and Shan, Xiaoou},
  title = {Clinical heterogeneity and therapeutic options for idiopathic infantile hypercalcemia caused by CYP24A1 pathogenic variant},
  journal = {Journal of Pediatric Endocrinology and Metabolism},
  year = {2023},
  doi = {10.1515/jpem-2023-0147}
}
Kostenlos starten →